Cav1.3 channel α1D protein is overexpressed and modulates androgen receptor transactivation in prostate cancers

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 5, 2014, Pages 524-536

  Chen, Ruibao ^a,e   Zeng, Xing ^a,e   Zhang, Ruitao ^a,b   Huang, Jiaoti ^c   Kuang, Xiangxing ^d   Yang, Jun ^e   Liu, Jihong ^e   Tawfik, Ossama ^a   Brantley Thrasher, James ^a   Li, Benyi ^a,b,d  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b Three Gorges University College of Medicine   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d GUANGDONG MEDICAL UNIVERSITY   (China)

^e HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Androgen receptor; CACNA1D; Calcium channel; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; CALCIUM CHANNEL L TYPE; COMPLEMENTARY DNA; MESSENGER RNA; ANDROGEN; AR PROTEIN, HUMAN; CACNA1D PROTEIN, HUMAN; CALCIUM;

CALCIUM TRANSPORT; CANCER TISSUE; CELL GROWTH; CONTROLLED STUDY; DATA BASE; GENE EXPRESSION PROFILING; GENE FUSION; GENE OVEREXPRESSION; GENETIC CODE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TRANSACTIVATION; TUMOR GENE; CELL PROLIFERATION; DISEASE COURSE; DNA MICROARRAY; GENE EXPRESSION REGULATION; MALE; METABOLISM; POLYMERASE CHAIN REACTION; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ANDROGENS; CALCIUM; CALCIUM CHANNELS, L-TYPE; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

EID: 84902524055     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.05.011     Document Type: Review

References (67)

1. Cain S.M., Snutch T.P. Voltage-gated calcium channels and disease. Biofactors 2011, 37:197-205.
2. 2+ channels. Physiol Rev 2010, 90:1461-1506.
3. Prevarskaya N., Skryma R., Shuba Y. Calcium in tumour metastasis: new roles for known actors. Nat Rev Cancer 2011, 11:609-618.
4. Engh A., Somasundaram A., Prakriya M. Permeation and gating mechanisms in store-operated CRAC channels. Front Biosci 2012, 17:1613-1626.
5. 2+]i waves in prostatic cells. Cell Calcium 1999, 25:297-311.
6. Wasilenko W.J., Palad A.J., Somers K.D., et al. Effects of the calcium influx inhibitor carboxyamido-triazole on the proliferation and invasiveness of human prostate tumor cell lines. Int J Cancer 1996, 68:259-264.
7. 2+-ATPases 2B involvement in human prostate cancer cell growth control. J Biol Chem 2001, 276:47608-47614.
8. Abdul M., Hoosein N. Inhibition by anticonvulsants of prostate-specific antigen and interleukin-6 secretion by human prostate cancer cells. Anticancer Res 2001, 21:2045-2048.
9. Steinsapir J., Socci R., Reinach P. Effects of androgen on intracellular calcium of LNCaP cells. Biochem Biophys Res Commun 1991, 179:90-96.
10. Lyng F.M., Jones G.R., Rommerts F.F. Rapid androgen actions on calcium signaling in rat sertoli cells and two human prostatic cell lines: similar biphasic responses between 1 picomolar and 100 nanomolar concentrations. Biol Reprod 2000, 63:736-747.
11. Gong Y., Blok L.J., Perry J.E., et al. Calcium regulation of androgen receptor expression in the human prostate cancer cell line LNCaP. Endocrinology 1995, 136:2172-2178.
12. Martikainen P., Isaacs J. Role of calcium in the programmed death of rat prostatic glandular cells. Prostate 1990, 17:175-187.
13. Connor J., Sawczuk I.S., Benson M.C., et al. Calcium channel antagonists delay regression of androgen-dependent tissues and suppress gene activity associated with cell death. Prostate 1988, 13:119-130.
14. Washington M.N., Weigel N.L. 1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion. Endocrinology 2010, 151:1409-1417.
15. Olsen J.H., Sorensen H.T., Friis S., et al. Cancer risk in users of calcium channel blockers. Hypertension 1997, 29:1091-1094.
16. Hole D.J., Gillis C.R., McCallum I.R., et al. Cancer risk of hypertensive patients taking calcium antagonists. J Hypertens 1998, 16:119-124.
17. Vezina R.M., Lesko S.M., Rosenberg L., Shapiro S. Calcium channel blocker use and the risk of prostate cancer. Am J Hypertens 1998, 11:1420-1425.
18. Debes J.D., Roberts R.O., Jacobson D.J., et al. Inverse association between prostate cancer and the use of calcium channel blockers. Cancer Epidemiol Biomarkers Prev 2004, 13:255-259.
19. Fitzpatrick A.L., Daling J.R., Furberg C.D., et al. Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. Ann Epidemiol 2001, 11:534-542.
20. Liao X., Tang S., Thrasher J.B., et al. Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol Cancer Ther 2005, 4:505-515.
21. Zhu Q., Youn H., Tang J., et al. Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers. Oncogene 2008, 27:4569-4579.
22. Xu W., Lipscombe D. Neuronal Ca(V)1.3alpha(1) L-type channels activate at relatively hyperpolarized membrane potentials and are incompletely inhibited by dihydropyridines. J Neurosci 2001, 21:5944-5951.
23. v3.2) T-type calcium channel during neuroendocrine differentiation of human prostate cancer cells. J Biol Chem 2002, 277:10824-10833.
24. Tomlins S.A., Rhodes D.R., Perner S., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
25. Lee S.O., Lou W., Hou M., et al. Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway. Oncogene 2003, 22:7981-7988.
26. Liu J., Youn H., Yang J., et al. G-protein alpha-s and -12 subunits are involved in androgen-stimulated PI3K activation and androgen receptor transactivation in prostate cancer cells. Prostate 2011, 71:1276-1286.
27. Huang J., Yao J.L., Zhang L., et al. Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer. Am J Pathol 2005, 166:1807-1815.
28. Sun A., Tawfik O., Gayed B., et al. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers. Prostate 2007, 67:203-213.
29. Welsh J.B., Sapinoso L.M., Su A.I., et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001, 61:5974-5978.
30. Magee J.A., Araki T., Patil S., et al. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 2001, 61:5692-5696.
31. Luo J.H., Yu Y.P., Cieply K., et al. Gene expression analysis of prostate cancers. Mol Carcinog 2002, 33:25-35.
32. LaTulippe E., Satagopan J., Smith A., et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 2002, 62:4499-4506.
33. Singh D., Febbo P.G., Ross K., et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002, 1:203-209.
34. Vanaja D.K., Cheville J.C., Iturria S.J., Young C.Y. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res 2003, 63:3877-3882.
35. Lapointe J., Li C., Higgins J.P., et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 2004, 101:811-816.
36. Yu Y.P., Landsittel D., Jing L., et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004, 22:2790-2799.
37. Varambally S., Yu J., Laxman B., et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005, 8:393-406.
38. Liu P., Ramachandran S., Ali Seyed M., et al. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res 2006, 66:4011-4019.
39. Tomlins S.A., Mehra R., Rhodes D.R., et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007, 39:41-51.
40. Wallace T.A., Prueitt R.L., Yi M., et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res 2008, 68:927-936.
41. Arredouani M.S., Lu B., Bhasin M., et al. Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer. Clin Cancer Res 2009, 15:5794-5802.
42. Taylor B.S., Schultz N., Hieronymus H., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18:11-22.
43. Grasso C.S., Wu Y.M., Robinson D.R., et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012, 487:239-243.
44. Scher H.I., Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005, 23:8253-8261.
45. Lin B., Ferguson C., White J.T., et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res 1999, 59:4180-4184.
46. Kumar-Sinha C., Tomlins S.A., Chinnaiyan A.M. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008, 8:497-511.
47. Tomlins S.A., Laxman B., Varambally S., et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008, 10:177-188.
48. Klezovitch O., Risk M., Coleman I., et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A 2008, 105:2105-2110.
49. Carver B.S., Tran J., Chen Z., et al. ETS rearrangements and prostate cancer initiation. Nature 2009, 457:E1. [discussion E2-3].
50. Wang J., Cai Y., Yu W., et al. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res 2008, 68:8516-8524.
51. Setlur S.R., Mertz K.D., Hoshida Y., et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 2008, 100:815-825.
52. Jhavar S., Brewer D., Edwards S., et al. Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. BJU Int 2009, 103:1256-1269.
53. Paulo P., Ribeiro F.R., Santos J., et al. Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements. Neoplasia 2012, 14:600-611.
54. Sun Y.H., Gao X., Tang Y.J., et al. Androgens induce increases in intracellular calcium via a G protein-coupled receptor in LNCaP prostate cancer cells. J Androl 2006, 27:671-678.
55. Liu C., Hermann T.E. Characterization of ionomycin as a calcium ionophore. J Biol Chem 1978, 253:5892-5894.
56. Sun A., Tang J., Terranova P.F., et al. Adeno-associated virus-delivered short hairpin-structured RNA for androgen receptor gene silencing induces tumor eradication of prostate cancer xenografts in nude mice: a preclinical study. Int J Cancer 2010, 126:764-774.
57. Schmidt L.J., Tindall D.J. Androgen receptor: past, present and future. Curr Drug Targets 2013, 14:401-407.
58. Lee S.O., Lou W., Hou M., et al. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 2003, 9:370-376.
59. Sharma R.K., Wang J.H., Wu Z. Mechanisms of inhibition of calmodulin-stimulated cyclic nucleotide phosphodiesterase by dihydropyridine calcium antagonists. J Neurochem 1997, 69:845-850.
60. Sutherland C., Walsh M.P. Activation of protein kinase C by the dihydropyridine calcium channel blocker, felodipine. Biochem Pharmacol 1989, 38:1263-1270.
61. Lamers J.M., Cysouw K.J., Verdouw P.D. Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol 1985, 34:3837-3843.
62. Bostrom S.L., Ljung B., Mardh S., et al. Interaction of the antihypertensive drug felodipine with calmodulin. Nature 1981, 292:777-778.
63. Scher H.I., Fizazi K., Saad F., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012, 367:1187-1197.
64. Ryan C.J., Smith M.R., de Bono J.S., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013, 368:138-148.
65. Zuccotti A., Clementi S., Reinbothe T., et al. Structural and functional differences between L-type calcium channels: crucial issues for future selective targeting. Trends Pharmacol Sci 2011, 32:366-375.
66. 2+ channels in human T cells: pharmacology and molecular characterization of the major alpha pore-forming and auxiliary beta-subunits. J Biol Chem 2004, 279:19566-19573.
67. Estrada M., Espinosa A., Muller M., Jaimovich E. Testosterone stimulates intracellular calcium release and mitogen-activated protein kinases via a G protein-coupled receptor in skeletal muscle cells. Endocrinology 2003, 144:3586-3597.